Unaudited financial results for the quarter ended 30th September 2026

November 04,2026 To, To, The Listing Compliance Department The Listing Department BSE Limited National Stock Exchange of India P.]. Towers, Dalal Street Limited Mumbai - 400001 Exchange Plaza, C-1, Block G Scrip Code: 524632 Bandra Kurla Complex, Bandra (East) Mumbai - 400051 Symbol: SHUKRAPHAR Dear Sir/Madam, Sub: of the Board Meeting hel ber 04, 2026 - Di: re under Regulati 0 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation: In continuation of our intimation dated October 23, 2026 and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we wish to inform you that the Board of Directors of the Company, at its meeting held on November 4, 2026, which commenced at 06.30 p.m. and concluded at 8.30 p.m,, inter alia, considered and approved the following: 1. The Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter and half year ended September 30, 2026, as recommended by the Audit Committee; Pursuant to Regulation 33 and other applicable regulations of the Listing Regulations, we enclose the unaudited Financial Results (Consolidated and Standalone) for the quarter and half year ended September 30, 2026 along with the Limited Review Reports issued by the Statutory Auditors thereon, are enclosed herewith. 2. Reviewed the other business of the company. You are requested to take the above information on records and disseminate the same on your website. Thanking you, Yours faithfully, For Shukra Medtech Limited (Formerly known as Shukra Pharmaceuticals Limited) Dakshesh Shah Director DIN: 00561666 Enclasaboye CIN : 124231GJ1993PLC019079 Regd. Office : 3rd Floor, “VEER HOUSE” Opp. WIAA Office, Judges Bunglow Road, Bodakdev, Ahmedabad - 380 054. Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhin- a38g27a21r, Gujarat, India, Ph. : 02764-286317 Email: info@shukrapharmaceuticals.com | Website: www.shukrapharamaceuticals.com STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 ] (All amounts in X Lakhs, Unless Otherwise Stated) . QUARTER ENDED HALF YEAR ENDED YEAR ENDED No, |Particulars 30.09.2026 30.06.2026 30.09.2025 30.09.2026 30.09.2025 31.03.2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1_|Income from Operations i[Revenue from Operations 422038 235223 587.74 6,772.61 1,12685 5,670.61 [ Other Income 57.20 53.97 171.26 1117 28223 45848 Total Income from Operations (+11) 4,477.58 2,406.20 759.00 6,883.78 1,409.08 6129.10 2_|Expenses (a) Cost of materials consumed 1,598.58 125.46 108081 1,724.04 955.96 1945.02 (b) Purchase of Stockin Trade - - - - - - (c) Changesi n inventories of finished goods, - (279.00) (88033) (279.00) (678.45) (360.12) and workein-progress and stock n trade (d) Employee Benefit Expenses 12722 24153 21933 368.75 40182 703.72 (e) Finance Cost EERY) 42.95 28.50 7617 5531 109.30 () Depreciation & Amortisation Expenses 11247 107.40 80.92 219.87 15964 344.27 (g) Other Expenses 49324 14363 209.93 63687 357.64 509.62 Total Expenses 2,364.73 38197 73916 2,746.70 1,251.92 325181 3_|Profit before Tax (1-2) 2,11285 2,024.23 19.84 4,137.08 157.16 2,877.29 4_|Tax Expenses I Current Tax 538.39 51682 - 1,055.21 40.59 73227 11 Deferred Tox (2674) 4.43 (217.96) (22.31) (224.20) (221.93) I Tax of Earler Year - - - - - 162.15 5_|Net Profit for the period / year (3-4) 1,601.20 1,502.98 23781 3,104.18 34077 2,208.79 6_|Other Comprehensive Income (net off Tax) Remeasurement of defined benefit plans - - - - - (8.72) Total Comprehensive Income for the period / 1,601.20 15028 237.81 310418 340.77 2,196.08 7_lyear (6+7) 8_|Paid up Equity Share Capital 4,407.87 4,378.79 437879 4,307.87 4,378.79 4,378.79 9 [Other Equity excluding revaluation reserve - B - - - 4,065.80 as at 315t March 10_|Face Value of Equity Shares 1.00 100 1.00 1.00 100 100 11_|Earnings per Share (of% 1/- each) : (a) Basic- X 036 033 005 071 0.08 0.50 (b) Diluted - % 0.36 033 005 071 0.08 050 NOTES: 1. The above Unaudited Standalone Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on Novembe0r4, 2026. | 2. The Unaudited Standalone Financial Results are prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 ("Act") | read with Companies (Indian Accounting Standards) Rules, 2015 as amended and in the format as prescribed under Regulation 33 of the SEBI (LODR) Regulations, 2015. The financial information presented above is extracted from and is harmonized to confirm with the Unaudited Standalone Financial Results. 3. The Unaudited Standalone Financial Results of the Company are available on Company’s website and also on the website of BSE Limited, i.e. www.bseindia.com, where the Shares of the Company are listed. 4. During the half year ended September 30, 2026, the Company received 0 investor complaints. Consequently, no investor complaint was pending as on September 30, 5. The figures for the previous period/year have been regrouped /reclassified , wherever necessary. 6. The Company is operating In two segments, namely “Shukra Pharmaceutical” and “Shukra MedTech'; accordingly, the above resuits pertain to both segments. Further, t 7.h e D us re ig nm ge tn ht e n haa lm f e y e“ aS rh u ek nr da e dM e Sd eT pe tc eh m” b ei rs e 3f 0f ,e c 2t 0i 2v 6e , f tr ho em CO oc mt po abe nr y 1 h, a2 s0 c2 o5 n vo en rw ta er dd s t. h e convertible warrants issued on a preferential basis in an earlier period into equity shares, Accordingly, the equity share capital of the Company has increased pursuant to the said conversion. 8. The name of the Company has been changed from Shukra Pharmaceuticals Limited to Shukra Medtech Limited ‘with effect from October 12, 2026. For and on behalf of the Board of Directors of SHUKRA MEDTECH LIMITED (FORMERLY KNOWN AS SHUKRA PHARMACEUTICALS LIMITED) Dakshesh Shah Place: Ahmedabad Director Date: November 04, 2026 DIN : 00561666 CIN : L24231GJ1993PLC019079 Regd. Office : 3rd Floor, “VEER HOUSE” Opp. WIAA Office, Judges Bunglow Road, Bodakdev, Anmedabad - 380 054. Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar - 382721, Gujarat, India, Ph. : 02764-286317 Email: info@shukrapharmaceuticals.com | Website: www.shukrapharamaceuticals.com ¢ ss Shulta Unaudited Standalone Statement of Assets and Liabilities as at September 30, 2026 (All amounts in X Lakhs, Unless Otherwise Stated) Asat Asat Particulars September 30, 2026 March 31, 2026 (Unaudited) (Audited) Assets Non-current assets Property, plant and equipment 2,090.74 217231 Capital work-in-progress 2,608.68 1,190.70 Investment 825 340 4,707.67 3,366.41 Current assets Inventories 2,34155 1,390.34 Financial assets (i) Trade receivables 3,871.13 2,208.76 (ii) Lo&a Adnvansces 530.25 223.09 (ili) Cash and cash equivalents 1,093.93 591.63 Other current assets 5,280.80 3,875.16 13,117.66 8,374.98 Total Assets 17,825.33 11,741.39 Equity and liabilities Equity Equity share capital 4,407.87 4378.79 Other equity 7,916.47 4,065.80 Money received against share warrants 67.02 538.66 Total Equity 12,391.36 8,983.25 Liabilities Non-current liabilities Financial liabilities (i) Borrowings 963.08 31929 Deferred tax labilities (net) 96.82 119.12 Long term provisions 33.27 1144 1,093.17 449.85 Current liabilities Financial liabilities (i) Borrowings 1,182.66 182.66 (ii) Trade payables 1,270.64 1,006.50 Other current lia 84.75 365.60 Short term provision 1,802.75 753.53 4,340.80 2,308.29 Total liabilities 5,433.97 2,758.14 Total equity and liabilities 17,825.33 11,741.39 For and on behalf of the Board of Directors of SHUKRA MEDTECH LIMITED (FORMERLY KNOWN AS | SHUKRA PHARMACEUTICALS LIMITED) Dakshesh Shah Place: Ahmedabad Director | Date: November 04, 2026 DIN : 00561666 | i E242316199 [Showing first 8,000 characters — download PDF for full document]